ADVERTISEMENT
DemeRx Begins Dosing Subjects in Study of Ibogaine for OUD
DemeRx, a Miami-based atai Life Sciences platform company that is developing ibogaine for the treatment of opioid use disorder, announced this week that the first subjects have been dosed in its Phase 1/2a clinical trial of ibogaine HCl (DMX-1002), an oral formulation of the psychedelic product that is isolated from a West African shrub.
Recreational drug users and healthy volunteers are being enrolled and dosed in the Phase 1 segment of the study at the Manchester clinical unit of MAC Clinical Research in the United Kingdom.
The Phase 1/2a trial is being conducted to assess safety, tolerability, movement of the drug in the body, and efficacy. Safety data from Phase 1 is expected to be available in early 2022.
“By launching the Phase1/2a trial, we look forward to bringing important data from carefully designed, controlled studies to the existing literature on ibogaine, a compound with substantial history,” said Dr Deborah Mash, CEO and president of DemeRx, said in a news release. “We are hopeful that this early trial can begin to establish a safe and efficacious profile for Ibogaine, so that we can potentially offer a new option for patients seeking to break free from OUD who have far too few options.”
